European equities tumbled on Wednesday to close sharply lower as investors reacted to sharp gains in the euro against the dollar.» Read More
The bank named Tom Willett as head of mergers and acquisitions, Europe. He will be based in London. Willett joins from Royal Bank of Scotland, where most recently he was chairman of corporate finance for Europe, the Middle East and Africa.
FRANKFURT, Oct 1- Evotec AG:. *Evotec and Bayer enter into multi-target alliance to fight endometriosis. up to approximately euro 580 million.
When we began planning our special report "Women in Business," I was eager to learn about how women are really doing in the workplace. In short, many women are successful, powerful and well off, but progress in the professional world has stalled.
With both global food prices and concerns about food safety on the rise, technology is playing a more important role in the economics of the world’s food supply.
An airplane needs to be safe in order for passengers to board it. Likewise, an airline CEO wants to feel the same clarity and certainty that so many of his c-suite compadres do in order to sustain growth.
European shares are indicated to open flat Friday, ahead of a conference at the European Central Bank in Frankfurt where Fed Chairman Ben Bernanke and ECB President Jean-Claude Trichet will both speak.
The jobs crisis has brought an unwelcome discovery for many unemployed Americans: job openings in their old fields exist. Yet they no longer qualify for them.
Shares in European airline and travel stocks fell heavily on Monday as ash from an Icelandic volcano looked set to bring much of Europe to a standstill for a 5th straight day.
I didn’t inhale. It’s the truth. I swear. I have never ever taken a toke on a joint or even a cigarette. Growing up, my parents were both smokers and I think I developed such a distaste for the constant cloud that it just never held any appeal for me.
At the risk of getting more emails from conspiracy-theorist readers who think I report too much negative news about Pfizer, here comes another setback for the world's biggest drug company.
On the Pfizer earnings conference call this morning Chairman and CEO Jeff Kindler kicked things off by calling this a "time of great uncertainty in the world economy and capital markets and significant challenges in our industry."
More than ten years after Pfizer brought Viagra to market and brought erectile dysfunction out of the closet a new survey says a lot of men are still too embarrassed to talk about impotence with their doctor.
A study claims "the time has come" for researchers to study ED drugs as preventive medicine for the heart.
If you watch "Project Runway," the future of judge Nina Garcia has been up in the air since she left Elle. Now we know the sort of career opportunities she's exploring. Not developing a new clothing line, or another magazine job, or designing shoes.
I like to think I have a nose for news. And, some might say, too much of a penchant for puns and alliteration. Impotence drug profits won't be going up big pharma's nose. The tiny New Jersey-based biotech company Palatin Technologies says it's giving up on its experimental nasal spray for erectile dysfunction.
Stocks ticked higher Monday amid merger buzz but index gains were modest as the market awaits the Federal Reserve's rate decision later this week.
Stocks retreated after an early pop Monday as the early market buzz was all about deals and deal makers.
Last night while on the elliptical and watching "NBC Nightly News," one spot amid the wall-to-wall commercials for drugs caught my attention. It looks like after 10 years since the first erectile dysfunction pill came on the market--Pfizer's Viagra celebrated a decade since winning FDA approval last week--the makers of Levitra are trying a new marketing tack.
When the economy rebounds, where's your portfolio going to be? UBS says that's a question to answer right now. The bank released what it calls its "'New' Nifty Fifty," a list of 50 companies from around the world that can use today's troubling market conditions to position themselves to thrive when the economy rebounds. (PART 2)
For a Monday before the Thanksgiving holiday, this is turning into an extremely busy day on the biotech beat. Two of the stories actually broke on Sunday: Celgene buying Pharmion for nearly $3 billion and Genentech announcing a breakthrough in brain cancer. Then, before the opening bell this morning Onyx Pharmaceuticals and Bayer won the expected Food and Drug Administration approval of their drug Nexavar for liver cancer.